Molecular Formula | C19H21N3O2S |
Molar Mass | 355.45 |
Solubility | Soluble in ethanol or DMSO |
Appearance | solid |
Color | yellow |
Storage Condition | Sealed in dry,2-8°C |
Sensitive | Light Sensitive |
In vitro study | Pretreatment of 501mel cells with ISCK03 inhibits SCF-induced c-kit phosphorylation dose dependently. ISCK03 also inhibits p44/42 ERK mitogen-activated protein kinase (MAPK) phosphorylation, which is known to be involved in SCF/c-kit downstream signaling. However ISCK03 does not inhibit hepatocyte growth factor (HGF)-induced phosphorylation of p44/42 ERK proteins. ISCK03, a tyrosine kinase inhibitor specific to KIT, prevents survival of CCDC26-KD cells under low-serum conditions. All treated cells exhibits sensitivity to ISCK03 in a dose-dependent manner. After ISCK03 treatment, the survival of KD cells is suppressed to the same level as that of non-KD cells. Conversely, ISCK03 treatment has limited effects on the growth of control K562 and KD clone 3–4 cells under high-serum concentration conditions. |
In vivo study | Oral administration of ISCK03 induces the dose-dependent depigmentation of newly regrown hair, and this is reversed with cessation of ISCK03 treatment. The topical application of ISCK03 promotes the depigmentation of UV-induced hyperpigmented spots. Fontana-Masson staining analysis shows epidermal melanin is diminished in spots treated with ISCK03. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36 - Irritating to the eyes |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 1 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.813 ml | 14.066 ml | 28.133 ml |
5 mM | 0.563 ml | 2.813 ml | 5.627 ml |
10 mM | 0.281 ml | 1.407 ml | 2.813 ml |
5 mM | 0.056 ml | 0.281 ml | 0.563 ml |